Acorda Therapeutics (Switzerland)

UPDRS-III score (primary endpoint) and PGIC changes after levodopa inhalation powder (CVT-301) 84mg treatment were compared for baseline subgroups of patients in the phase 3, SPAN-PD study.

Multiple sclerosis (Ms) is a chronic, disabling condition with severe clinical and social consequences. glatiramer acetate (gA) has been widely used for more than 15 years as a first-line disease-modifying agent in the treatment of relapsing–remitting Ms (rrMs). it appears to have multiple modes of action, including the induction of gA-reactive T-helper 2 (Th2) immunoregulatory cells and the stimulation of neurotrophin secretion in the central nervous system, which may promote neuronal repair. clinical trial data show that gA reduces the relapse rate in rrMs, can delay or halt disability progression, and brings about improvement in magnetic resonance imaging (Mri) measures of disease activity, including reduction of brain atrophy. early treatment with gA can reduce the risk of developing clinically definite Ms in patients with clinically isolated syndrome. furthermore, it has an excellent safety and tolerability profile. recent data from patients treated for 15 years have indicated that more than half of the patients on long-term gA therapy have stable or improved disability scores.